Last reviewed · How we verify
ketamine- dexmeditomidine admixure
This admixture combines ketamine (an NMDA receptor antagonist) with dexmedetomidine (an alpha-2 adrenergic agonist) to provide dissociative anesthesia with sedation and analgesia.
This admixture combines ketamine (an NMDA receptor antagonist) with dexmedetomidine (an alpha-2 adrenergic agonist) to provide dissociative anesthesia with sedation and analgesia. Used for Anesthesia induction and maintenance, Sedation in intensive care settings.
At a glance
| Generic name | ketamine- dexmeditomidine admixure |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Drug class | Dissociative anesthetic with alpha-2 adrenergic agonist |
| Target | NMDA receptor (ketamine); alpha-2 adrenergic receptor (dexmedetomidine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ketamine blocks NMDA glutamate receptors to produce dissociative anesthesia and analgesia while maintaining airway reflexes. Dexmedetomidine acts as a selective alpha-2 adrenergic agonist to enhance sedation, reduce anxiety, and provide additional analgesia. The combination is used clinically to achieve balanced anesthesia with improved hemodynamic stability and reduced emergence reactions compared to ketamine alone.
Approved indications
- Anesthesia induction and maintenance
- Sedation in intensive care settings
Common side effects
- Emergence reactions/dissociation
- Hypertension
- Tachycardia
- Bradycardia
- Hypotension
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketamine- dexmeditomidine admixure CI brief — competitive landscape report
- ketamine- dexmeditomidine admixure updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI